Browsing “Market AccessMarket Access | EVERSANA”

Is ICER Increasing Influence in the U.S. Over Time?

Recent high-profile product launches have reignited the debate on healthcare costs in the US. The Institute for Clinical and Economic Review (ICER) is an independent research organization that determines value-based price benchmarks. In a recent study, Dr. Stino, Product Manager, examined recent high-profile launches to understand the interaction between ICER value-based price benchmarks and actual […]

Improving the Impact of an Oncology Patient Access Program

Our client, a specialty pharmaceutical company focused on the research and development of new therapies in two high-cost complex drug categories, sought to benchmark its patient assistance program against those of its competitors in order to improve relationships within target oncologists’ offices. The Challenge The client needed to assess the image of its patient assistance […]

ICER’s Unsupported Price Increase Assessment

In October 2019, the Institute of Clinical and Economic Review (ICER) released their first annual report on Unsupported Price Increases of prescription drugs in the United States. The report takes a systematic approach to determine whether certain price increases are justified by new clinical evidence or other factors. Our Health Strategies Insights team conducted a […]

U.S. physicians disagree with Germany’s determinations of the value of diabetes medicines

According to a recent study from Health Strategies Insights by EVERSANA, 89% of U.S. physicians disagree with Germany’s determinations of the clinical benefit of innovative diabetes medicines. Learn more about our Market Access products & capabilities! Contact us with your questions and data needs, and an expert will follow up shortly.

Rethinking Patient Centricity in a Dynamic Market Access Driven Ecosystem

Understanding the Complexities and Interdependencies that Deliver Successful Outcomes. As the industry moves to a patient-centric, value-based care model, stakeholders across the continuum of care are focused on creating systems and solutions that put the patient at the forefront of decision making. This requires an alignment of priorities, such as patient engagement, HCP practice efficiency, […]

Strategies to Ensure Market Success of a Rare Disease Product Launch

Small patient populations, complex administration, high costs of therapies, and government policy interventions are just a few obstacles in rare disease. EVERSANA’s Managing Director, Bill O’Bryon, and Senior Director, Diann Johnson, outline key insights to consider in your launch strategy: Market dynamics impacting rare disease therapies The entire rare community: patients, caregivers, providers & advocates […]

What’s next for ICER? Pharmaceutical pricing watchdog to venture beyond the pill.

Earlier in the month, the Institute for Clinical and Economic Review (ICER) issued a call for public input to help identify and prioritize non-drug topics for ICER assessments in 2020. It may seem like the ICER has always been focused on driving down the price of drugs, conducing health technology assessments to properly calculate the […]

Developing an Optimal Hub to Ensure Product Access

Prior to launching a new Hub, our client, a global biopharmaceutical company, needed to ensure that the services offered would be superior to those of other companies and ensure their product’s access in an increasingly competitive category. The Challenge Our client’s product was one of only a handful of FDA-approved products in a specific category. […]

Decoding ICER: Successful Pharma Engagement with ICER for U.S. HTA Review

How pharmaceutical and Biotech companies engaged ICER drives the outcome. Reactive responses to ICER review have led to poor outcomes and numerous downstream impacts to payer access and pricing. Cohesive enterprise engagement has demonstrated significantly better recommendations and less pressure for the US payer community. Unfortunately, ‘reactive-response’ is more common than ‘enterprise engagement.’ KEY SUCCESS […]

Challenges and Best Practices in Managing Value Based Contracts

Manufacturers face a variety of hurdles when negotiating value based contracts: from data access and standardization, deal structure variation, payment variability and scheduling, to changing laws and regulations. And, as the industry shifts to value-driven healthcare, the demand for innovative product commercialization and pricing models grows. In this webinar EVERSANA experts Robert Blank and Mike […]